Technical Analysis for CGON - CG Oncology, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 29.98 | -3.20% | -0.99 |
CGON closed down 3.2 percent on Friday, May 17, 2024, on 89 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Multiple of Ten Bullish | Other | -3.20% | |
| Wide Bands | Range Expansion | -3.20% | |
| Up 3 Days in a Row | Strength | -3.20% | |
| Oversold Stochastic | Weakness | -3.20% | |
| Wide Bands | Range Expansion | 7.03% |
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| Possible Inside Day | 1 day ago |
| Down 5% | 1 day ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| Down 3% | 2 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already been completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Virotherapy Immunotherapies Oncolytic Virus
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Virotherapy Immunotherapies Oncolytic Virus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 50.23 |
| 52 Week Low | 25.77 |
| Average Volume | 674,608 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 36.94 |
| 20-Day Moving Average | 34.26 |
| 10-Day Moving Average | 30.21 |
| Average True Range | 3.38 |
| RSI (14) | 40.12 |
| ADX | 27.04 |
| +DI | 16.24 |
| -DI | 27.50 |
| Chandelier Exit (Long, 3 ATRs) | 36.84 |
| Chandelier Exit (Short, 3 ATRs) | 35.92 |
| Upper Bollinger Bands | 44.14 |
| Lower Bollinger Band | 24.37 |
| Percent B (%b) | 0.28 |
| BandWidth | 57.73 |
| MACD Line | -2.64 |
| MACD Signal Line | -2.12 |
| MACD Histogram | -0.5204 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 32.87 | ||||
| Resistance 3 (R3) | 32.96 | 32.08 | 32.39 | ||
| Resistance 2 (R2) | 32.08 | 31.34 | 32.04 | 32.23 | |
| Resistance 1 (R1) | 31.03 | 30.89 | 30.59 | 30.94 | 32.07 |
| Pivot Point | 30.15 | 30.15 | 29.93 | 30.11 | 30.15 |
| Support 1 (S1) | 29.10 | 29.41 | 28.66 | 29.02 | 27.89 |
| Support 2 (S2) | 28.22 | 28.96 | 28.18 | 27.73 | |
| Support 3 (S3) | 27.17 | 28.22 | 27.57 | ||
| Support 4 (S4) | 27.09 |
